Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
A yearly supply of Pomalyst may cost around $147,302 (without insurance)
MMIT, 2024
L., Comelli, E
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors
Most current guidelines (CDC, WHO) no longer require aspiration for subcutaneous injections because blood vessels in fatty tissue are small and hitting one is rare
Tirzepatide (Mounjaro) Healthcare Professional Information
US$ 25.47
US$ 21.53
US$ 25.87
US$ 25.51
US$ 20.24
US$ 27.62
US$ 20.04
US$ 29.57
US$ 20.69
US$ 20.12
US$ 27.29
US$ 29.38
